modelAbacavir
Extends from Pharmacolibrary.Drugs.ATC.J.J05AF06.
Information
| name: | Abacavir | |
| ATC code: | J05AF06 | route: | oral |
| compartments: | 1 | |
| dosage: | 600 | mg |
| volume of distribution: | 0.86 | L |
| clearance: | 15 | L/h |
| other parameters in model implementation | ||
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of antiretroviral therapy (ART) for the treatment of HIV-1 infection in adults and children. It is approved for use in combination with other antiretroviral agents.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects after oral administration.
References
Zhao, W, et al., & Jacqz-Aigrain, E (2013). Population pharmacokinetics of abacavir in infants, toddlers and children. British journal of clinical pharmacology 75(6) 1525–1535. DOI:10.1111/bcp.12024 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23126277
Zhao, W, et al., & Jacqz-Aigrain, E (2012). Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. British journal of clinical pharmacology 73(4) 641–650. DOI:10.1111/j.1365-2125.2011.04121.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21988586
Singh, RP, et al., & Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development 10(9) 985–993. DOI:10.1002/cpdd.996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34265164
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)